KR102186924B1 - 출혈 장애를 치료하기 위한 변형된 세르핀 - Google Patents

출혈 장애를 치료하기 위한 변형된 세르핀 Download PDF

Info

Publication number
KR102186924B1
KR102186924B1 KR1020197006015A KR20197006015A KR102186924B1 KR 102186924 B1 KR102186924 B1 KR 102186924B1 KR 1020197006015 A KR1020197006015 A KR 1020197006015A KR 20197006015 A KR20197006015 A KR 20197006015A KR 102186924 B1 KR102186924 B1 KR 102186924B1
Authority
KR
South Korea
Prior art keywords
leu
residue
thr
ser
ala
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020197006015A
Other languages
English (en)
Korean (ko)
Other versions
KR20190022945A (ko
Inventor
제임스 앤드류 헌팅톤
스테파니 폴데르디즈크
트레버 베이글린
Original Assignee
캠브리지 엔터프라이즈 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 캠브리지 엔터프라이즈 리미티드 filed Critical 캠브리지 엔터프라이즈 리미티드
Publication of KR20190022945A publication Critical patent/KR20190022945A/ko
Application granted granted Critical
Publication of KR102186924B1 publication Critical patent/KR102186924B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
    • C07K14/8121—Serpins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L24/00—Surgical adhesives or cements; Adhesives for colostomy devices
    • A61L24/001—Use of materials characterised by their function or physical properties
    • A61L24/0015—Medicaments; Biocides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
    • A61L26/0009—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form containing macromolecular materials
    • A61L26/0028—Polypeptides; Proteins; Degradation products thereof
    • A61L26/0047—Specific proteins or polypeptides not covered by groups A61L26/0033 - A61L26/0042
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
    • C07K14/8121—Serpins
    • C07K14/8125—Alpha-1-antitrypsin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
    • A61L2300/252—Polypeptides, proteins, e.g. glycoproteins, lipoproteins, cytokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
    • A61L2300/258—Genetic materials, DNA, RNA, genes, vectors, e.g. plasmids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/418—Agents promoting blood coagulation, blood-clotting agents, embolising agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2400/00—Materials characterised by their function or physical properties
    • A61L2400/04—Materials for stopping bleeding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Materials Engineering (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Surgery (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
KR1020197006015A 2013-12-13 2014-12-15 출혈 장애를 치료하기 위한 변형된 세르핀 Active KR102186924B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1322091.8A GB201322091D0 (en) 2013-12-13 2013-12-13 Modified serpins for the treatment of bleeding disorders
GB1322091.8 2013-12-13
PCT/EP2014/077783 WO2015086854A1 (en) 2013-12-13 2014-12-15 Modified serpins for the treatment of bleeding disorders

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020167018756A Division KR101954945B1 (ko) 2013-12-13 2014-12-15 출혈 장애를 치료하기 위한 변형된 세르핀

Publications (2)

Publication Number Publication Date
KR20190022945A KR20190022945A (ko) 2019-03-06
KR102186924B1 true KR102186924B1 (ko) 2020-12-04

Family

ID=50030900

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020197006015A Active KR102186924B1 (ko) 2013-12-13 2014-12-15 출혈 장애를 치료하기 위한 변형된 세르핀
KR1020167018756A Active KR101954945B1 (ko) 2013-12-13 2014-12-15 출혈 장애를 치료하기 위한 변형된 세르핀

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020167018756A Active KR101954945B1 (ko) 2013-12-13 2014-12-15 출혈 장애를 치료하기 위한 변형된 세르핀

Country Status (25)

Country Link
US (2) US9982035B2 (cg-RX-API-DMAC7.html)
EP (2) EP3080157B1 (cg-RX-API-DMAC7.html)
JP (2) JP6431541B2 (cg-RX-API-DMAC7.html)
KR (2) KR102186924B1 (cg-RX-API-DMAC7.html)
CN (2) CN110330563B (cg-RX-API-DMAC7.html)
AU (2) AU2014363359B2 (cg-RX-API-DMAC7.html)
CA (1) CA2933508C (cg-RX-API-DMAC7.html)
CY (1) CY1121267T1 (cg-RX-API-DMAC7.html)
DK (1) DK3080157T3 (cg-RX-API-DMAC7.html)
EA (1) EA034050B1 (cg-RX-API-DMAC7.html)
ES (1) ES2704058T3 (cg-RX-API-DMAC7.html)
GB (1) GB201322091D0 (cg-RX-API-DMAC7.html)
HR (1) HRP20182138T1 (cg-RX-API-DMAC7.html)
HU (1) HUE042763T2 (cg-RX-API-DMAC7.html)
IL (2) IL246180B (cg-RX-API-DMAC7.html)
LT (1) LT3080157T (cg-RX-API-DMAC7.html)
MX (1) MX357941B (cg-RX-API-DMAC7.html)
NZ (1) NZ721918A (cg-RX-API-DMAC7.html)
PL (1) PL3080157T3 (cg-RX-API-DMAC7.html)
PT (1) PT3080157T (cg-RX-API-DMAC7.html)
RS (1) RS58191B1 (cg-RX-API-DMAC7.html)
SI (1) SI3080157T1 (cg-RX-API-DMAC7.html)
SM (1) SMT201900016T1 (cg-RX-API-DMAC7.html)
TR (1) TR201819781T4 (cg-RX-API-DMAC7.html)
WO (1) WO2015086854A1 (cg-RX-API-DMAC7.html)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010045659A1 (en) 2008-10-17 2010-04-22 American Gene Technologies International Inc. Safe lentiviral vectors for targeted delivery of multiple therapeutic molecules
GB201322091D0 (en) 2013-12-13 2014-01-29 Cambridge Entpr Ltd Modified serpins for the treatment of bleeding disorders
US11980663B2 (en) 2015-07-08 2024-05-14 American Gene Technologies International Inc. HIV pre-immunization and immunotherapy
IL297238B2 (en) 2016-01-15 2024-08-01 American Gene Tech Int Inc Methods and preparations for gamma-delta T-cell activation
JP7153332B2 (ja) 2016-02-08 2022-10-14 アメリカン ジーン テクノロジーズ インターナショナル インコーポレイテッド Ｈｉｖワクチン接種および免疫療法
ES2911448T3 (es) 2016-03-09 2022-05-19 American Gene Tech Int Inc Vectores combinados y métodos para el tratamiento del cáncer
WO2017213697A1 (en) 2016-06-08 2017-12-14 American Gene Technologies International Inc. Non-integrating viral delivery system and methods related thereto
CA3028982A1 (en) 2016-07-08 2018-01-11 American Gene Technologies International Inc. Hiv pre-immunization and immunotherapy
WO2018154044A1 (en) * 2017-02-23 2018-08-30 Umc Utrecht Holding B.V. Modified serpins for the treatment of bradykinin-mediated disease
US11820999B2 (en) 2017-04-03 2023-11-21 American Gene Technologies International Inc. Compositions and methods for treating phenylketonuria
RU2663464C1 (ru) * 2018-02-26 2018-08-06 Общество с ограниченной ответственностью "Международный Биотехнологический Центр "Генериум" Комбинаторная терапия для лечения геморрагического шока
WO2020092448A1 (en) * 2018-10-29 2020-05-07 Spin Therapeutics, Llc Compositions and methods for alpha-1-antitrypsin disorders
CN110051830A (zh) * 2019-03-14 2019-07-26 苏州新凝生物医药科技有限公司 一种protease nexin II\KPI蛋白突变体的应用
EP4326869A4 (en) * 2021-04-20 2025-12-10 Univ Of Louisville RECOMBINATING MICRO-NECK
EP4453012A1 (en) 2021-12-22 2024-10-30 Royal College of Surgeons in Ireland A conjugate for use in localising a molecule to the vascular endothelium
EP4707391A1 (en) * 2024-09-10 2026-03-11 e-therapeutics PLC Nucleic acid compounds for zpi inhibition

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4711848A (en) 1984-03-14 1987-12-08 Zymogenetics, Inc. Site specific mutagenesis in alpha-1-antitrypsin
FR2599752B1 (fr) 1986-06-10 1989-11-03 Transgene Sa Variants de l'alpha1- antitrypsine utiles notamment comme inhibiteurs de la kallikreine
DE3705745A1 (de) 1987-02-23 1988-09-01 Behringwerke Ag Protein c-inhibitor (pci) als pharmazeutikum und in vitro-diagnostikum, verfahren zur herstellung eines solchen pharmazeutikums oder diagnostikums sowie ein mittel enthaltend pci
US5612194A (en) 1989-06-23 1997-03-18 Trustees Of The University Of Pennsylvania Methods of producing effective recombinant serine protease inhibitors and uses of these inhibitors
IE902276A1 (en) 1989-06-26 1991-01-16 Akzo Nv Serpin variants
CA2272095A1 (en) 1996-11-19 1998-05-28 Saulius Butenas Peptidomimetics containing 6-peptidylamino-1-naphthalenesulfonamide moieties
WO2001055390A1 (en) 2000-01-28 2001-08-02 Human Genome Sciences, Inc. Human serpin polynucleotides, polypeptides, and antibodies
JP2002010783A (ja) 2000-06-29 2002-01-15 Jcr Pharmaceuticals Co Ltd 改変型ヒトプロテインｃインヒビター
US6924267B2 (en) 2001-09-18 2005-08-02 Suomen Punainen Risti Veripalvelu Methods and active substances for protecting organs
JP2003093063A (ja) 2001-09-20 2003-04-02 Jcr Pharmaceuticals Co Ltd 改変型ヒトプロテインｃインヒビター
WO2003039585A1 (en) 2001-11-09 2003-05-15 Novo Nordisk Health Care Ag Pharmaceutical composition comprising factor vii polypeptides and protein c inhibitors
FR2836143B1 (fr) 2002-02-21 2004-04-16 Servier Lab Nouveaux derives d'acides amines, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
CA2508276C (en) 2002-12-05 2018-03-27 Socratech L.L.C. Neuroprotective activity of activated protein c is independent of its anticoagulant activity
WO2004056309A2 (en) 2002-12-05 2004-07-08 Socratech L.L.C. Neuroprotective activity of activated protein c is independent of its anticoagulant activity
WO2006090282A2 (en) * 2005-02-28 2006-08-31 Universite De Lausanne Recombinant inhibitor proteins of an hk14 protease and use thereof
EP1894574A4 (en) 2005-04-18 2011-05-18 Univ Mie ANTICROBIAL AGENTS WITH PROTEIN C INHIBITOR
EP1960266B1 (en) * 2005-12-15 2019-02-20 Gulfstream Aerospace Corporation Isentropic compression inlet for supersonic aircraft
ES2372709T3 (es) * 2006-07-05 2012-01-25 Catalyst Biosciences, Inc. Procedimientos de cribado de proteasas y proteasas identificadas por los mismos.
WO2008059009A2 (en) 2006-11-16 2008-05-22 Crucell Holland B.V. Factor v mutants for hemostasis in hemophilia
WO2008059041A2 (en) 2006-11-16 2008-05-22 Crucell Holland B.V. Complementation of factor xi deficiency by factor v mutants
WO2008059043A2 (en) 2006-11-16 2008-05-22 Crucell Holland B.V. Combination of coagulation factor viii with apc-resistant factor v
WO2009013251A1 (en) 2007-07-20 2009-01-29 Universite Paris-Sud Xi Use of mutated antithrombins for treating or preventing coagulation disorders
GB0714649D0 (en) 2007-07-27 2007-09-05 Univ Leuven Kath Novel viral replication inhibitors
BRPI0818865A2 (pt) 2007-10-26 2015-05-05 Oklahoma Med Res Found Anticorpos monoclonais contra proteína c ativada.
EP2055783A1 (en) * 2007-10-30 2009-05-06 VIB vzw Insect inhibiting plant serpin mutants
CA2703948A1 (en) 2007-11-01 2009-05-07 University Of Rochester Recombinant factor viii having increased stability
AU2009207394B2 (en) * 2008-01-21 2015-01-22 Dermadis Sa Use of serine protease inhibitors in the treatment of skin diseases
US8822654B2 (en) 2009-01-16 2014-09-02 Universite Paris—Sud XI Mutated antithrombins, a process for preparing the same and their use as drugs
CN102439044B (zh) * 2009-04-22 2014-08-13 阿特根公司 通过体内持续释放维持的体内半衰期增加的融合蛋白质或融合肽以及使用所述融合蛋白质或融合肽增加体内半衰期的方法
WO2011123830A2 (en) * 2010-04-02 2011-10-06 Amunix Operating Inc. Alpha 1-antitrypsin compositions and methods of making and using same
US9127274B2 (en) 2012-04-26 2015-09-08 Alnylam Pharmaceuticals, Inc. Serpinc1 iRNA compositions and methods of use thereof
CN105431165A (zh) 2013-05-15 2016-03-23 莫尔研究应用有限公司 用于治疗心肺手术后的术后并发症的组合物和方法
GB201322091D0 (en) 2013-12-13 2014-01-29 Cambridge Entpr Ltd Modified serpins for the treatment of bleeding disorders
WO2018154044A1 (en) * 2017-02-23 2018-08-30 Umc Utrecht Holding B.V. Modified serpins for the treatment of bradykinin-mediated disease

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
J. Bio.l Chem. (2009), Vol 284, No.51, pp35652-35682.*
Journal of Biological Chemistry, Vol. 277, No. 33, pp29927-29935(2002)

Also Published As

Publication number Publication date
NZ721918A (en) 2019-12-20
HUE042763T2 (hu) 2019-07-29
KR101954945B1 (ko) 2019-03-07
CA2933508C (en) 2021-04-06
JP2019037242A (ja) 2019-03-14
TR201819781T4 (tr) 2019-01-21
EP3080157B1 (en) 2018-10-03
ES2704058T3 (es) 2019-03-14
CY1121267T1 (el) 2020-05-29
LT3080157T (lt) 2018-12-10
US9982035B2 (en) 2018-05-29
BR112016013591A2 (pt) 2017-10-03
DK3080157T3 (en) 2018-12-17
EA201691235A1 (ru) 2016-12-30
EP3434689A1 (en) 2019-01-30
JP6723319B2 (ja) 2020-07-15
EA034050B1 (ru) 2019-12-23
WO2015086854A1 (en) 2015-06-18
JP6431541B2 (ja) 2018-11-28
CA2933508A1 (en) 2015-06-18
KR20160092025A (ko) 2016-08-03
JP2017505114A (ja) 2017-02-16
AU2018279054A1 (en) 2019-01-17
IL246180A0 (en) 2016-07-31
US20180273610A1 (en) 2018-09-27
RS58191B1 (sr) 2019-03-29
MX2016007711A (es) 2016-12-09
US10351619B2 (en) 2019-07-16
GB201322091D0 (en) 2014-01-29
CN105992771B (zh) 2019-08-23
EP3080157A1 (en) 2016-10-19
CN105992771A (zh) 2016-10-05
SI3080157T1 (sl) 2018-12-31
PL3080157T3 (pl) 2019-03-29
HRP20182138T1 (hr) 2019-02-08
AU2014363359A1 (en) 2016-07-21
CN110330563A (zh) 2019-10-15
US20160311887A1 (en) 2016-10-27
PT3080157T (pt) 2019-01-11
IL246180B (en) 2018-11-29
AU2014363359B2 (en) 2019-01-03
KR20190022945A (ko) 2019-03-06
MX357941B (es) 2018-07-31
SMT201900016T1 (it) 2019-02-28
CN110330563B (zh) 2024-03-29
IL262879A (en) 2018-12-31

Similar Documents

Publication Publication Date Title
JP6723319B2 (ja) 出血性障害の治療に対する改変セルピン
KR102473014B1 (ko) 장기-작용성 응고 인자 및 그의 제조 방법
JP2017114889A (ja) 再構成後の精製第ｖｉｉｉ因子の安定性を改善するための方法
JP2013531651A (ja) 線溶亢進を伴う凝固障害の処置
CN101952422A (zh) 化学修饰的因子ix
WO2023246680A1 (en) Activators of coagulation factor x and formulations thereof for treating bleeding disorders
BR112016013591B1 (pt) Serpina modificada, célula recombinante que expressa a serpina, composição farmacêutica compreendendo a serpina e uso da serpina modificada para o tratamento ou prevenção de hemorragia ou para promoção de hemostasia
KR102597725B1 (ko) 혈우병의 예방적 치료를 위해 인자 ix 및 사람 알부민을 포함하는 융합 단백질에 대한 21-일 투여 용법 및 이의 방법
HK1229344B (en) Modified serpins for the treatment of bleeding disorders
HK1229344A1 (en) Modified serpins for the treatment of bleeding disorders
CN104395465A (zh) 表现出外位点介导的超级活性的FVIIa-sTF复合物

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A18-div-PA0104

St.27 status event code: A-0-1-A10-A16-div-PA0104

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

R17-X000 Change to representative recorded

St.27 status event code: A-5-5-R10-R17-oth-X000

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 6

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-OTH-PR1001 (AS PROVIDED BY THE NATIONAL OFFICE)

Year of fee payment: 6